摘要
目的:明确我国医药制造业中不同规模企业经济效益的差距,为提高产业集中度提供参考。方法:根据《中国高技术产业统计年鉴2012》的统计数据,对2011年我国大、中、小型医药企业的劳动生产率、资产周转率、总资产利润率、销售利润率、产品销售率等情况进行对比分析。结果:在2011年和2010年,我国医药制造业中的大、中、小型医药企业的劳动生产率(万元/人)分别为77.1、73.4、101.4和67.5、63.3、72.7;总资产周转率(次)分别为0.99、0.96、1.39和0.97、0.89、1.24;总资产利润率分别为11.55%、12.56%、12.56%和11.36%、12.82%、11.43%;销售利润率分别为11.68%、13.12%、9.07%和11.69%、14.42%、9.21%;产品销售率分别为102.31%、92.76%、95.50%和107.96%、93.21%、94.90%。结论:我国大型医药企业除产品销售率领先于中、小型医药企业外,其他4项指标均不同程度落后于中、小型医药企业。与2010年比较,2011年小型医药企业在劳动生产率、总资产周转率、总资产利润率和产品销售率方面增速较快,在销售利润率方面各类型企业均有不同程度的下降。医药制造企业应加快改革步伐,尤其是大型医药企业更要协调好稳定与发展的关系,保证稳中有升,争取实现跨越式增长,以提高产业集中度。
OBJECTIVE： To clear the economic gap among different scales of pharmaceutical enterprises in China, and to pro- vide recommendations to improve industrial concentration. METHODS： According to China Statistical Yearbook on High Technolo- gy Industry （2012）, large, medium and small scales of pharmaceutical enterprises were analyzed in terms of labor productivity, as- set turnover, total assets profit margin, return on sales, product sales rate, etc. RESULTS： In 2011 and 2010, the labor productivi- ty （10 000 yuan/person） of large, medium and small scales of pharmaceutical enterprises were 77.1, 73.4, 101.4 and 67.5, 63.3, 72.7; asset turnover （times） were 0.99, 0.96, 1.39 and 0.97, 0.89, 1.24; total assets profit margin were 11.55% , 12.56%, 12.56% and 11.36%, 12.82%, 11.43% ; return on sales were 11.68%, 13.12%, 9.07% and 11.69%, 14.42%, 9.21% ; product sales rate were 102.31%, 92.76%, 95.50% and 107.96%, 93.21%, 94.90%. CONCLUSIONS： In 2011, product sales rate of large-scale pharmaceutical enterprises ran ahead of those of medium and small scale enterprises, but other indicators fell behind those of medium and small scale enterprises. Compared with 2010, small pharmaceutical enterprises grew rapidly in 2011 in re- spects of labor productivity, total asset turnover, total assets profit margin and product sales rate, while return on sales of different scales of enterprises decreased to different extent. Pharmaceutical enterprises should accelerate reforms, especially large enterprises should coordinate the stability and development, to ensure steady increase towards growth by leaps and bounds to improve industri- al concentration.
出处
《中国药房》
CAS
CSCD
2014年第13期1153-1155,共3页
China Pharmacy
关键词
医药制造业
规模
经济效益
比较
Pharmaceutical enterprises
Scale
Economic benefits
Comparison
